English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/167772
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance

AuthorsGrasse, Sabrina; Lienhard, Matthias; Frese, Steffen; Kerick, Martin; Steinbach, Anne; Grimm, Christina; Hussong, Michelle; Rolff, Jana; Becker, Michael; Dreher, Felix; Schirmer, Uwe; Boerno, Stefan; Ramisch, Anna; Leschber, Gunda; Timmermann, Bernd; Grohé, Christian; Lüders, Heike; Vingron, Martin; Fichtner, Iduna; Klein, Sebastian; Odenthal, Margarete; Büttner, Reinhard; Lehrach, Hans; Sültmann, Holger; Herwig, Ralf; Schweiger, Michal R.
KeywordsNon-small cell lung cancer
NSCLC
Epigenomics
Predictive biomarker
Therapy response
DNA methylation
Patient-derived xenografts
Carboplatin resistance
Issue Date20-Jul-2018
PublisherBioMed Central
CitationGenome Medicine 10(1): 55 (2018)
Abstract[Background] Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide and is primarily treated with radiation, surgery, and platinum-based drugs like cisplatin and carboplatin. The major challenge in the treatment of NSCLC patients is intrinsic or acquired resistance to chemotherapy. Molecular markers predicting the outcome of the patients are urgently needed.
[Methods] Here, we employed patient-derived xenografts (PDXs) to detect predictive methylation biomarkers for platin-based therapies. We used MeDIP-Seq to generate genome-wide DNA methylation profiles of 22 PDXs, their parental primary NSCLC, and their corresponding normal tissues and complemented the data with gene expression analyses of the same tissues. Candidate biomarkers were validated with quantitative methylation-specific PCRs (qMSP) in an independent cohort.
[Results] Comprehensive analyses revealed that differential methylation patterns are highly similar, enriched in PDXs and lung tumor-specific when comparing differences in methylation between PDXs versus primary NSCLC. We identified a set of 40 candidate regions with methylation correlated to carboplatin response and corresponding inverse gene expression pattern even before therapy. This analysis led to the identification of a promoter CpG island methylation of LDL receptor-related protein 12 (LRP12) associated with increased resistance to carboplatin. Validation in an independent patient cohort (n = 35) confirmed that LRP12 methylation status is predictive for therapeutic response of NSCLC patients to platin therapy with a sensitivity of 80% and a specificity of 84% (p < 0.01). Similarly, we find a shorter survival time for patients with LRP12 hypermethylation in the TCGA data set for NSCLC (lung adenocarcinoma).
[Conclusions] Using an epigenome-wide sequencing approach, we find differential methylation patterns from primary lung cancer and PDX-derived cancers to be very similar, albeit with a lower degree of differential methylation in primary tumors. We identify LRP12 DNA methylation as a powerful predictive marker for carboplatin resistance. These findings outline a platform for the identification of epigenetic therapy resistance biomarkers based on PDX NSCLC models.
Publisher version (URL)https://doi.org/10.1186/s13073-018-0562-1
URIhttp://hdl.handle.net/10261/167772
DOI10.1186/s13073-018-0562-1
ISSN1756-994X
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
epigenomic_resistance_2018.pdf2,44 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.